BroadPharm has a highly skilled technical team and state-of-the-art facilities, coupled with extensive experience in research, development, and production. We offer comprehensive, one-stop services for the design, synthesis, purification, optimization, analysis, and evaluation of ADC-related products.
Our services include:
We provide a variety of linkers, including both cleavable and non-cleavable options. Cleavable linkers include enzyme-cleavable, disulfide, and acid-labile linkers. BroadPharm stocks an extensive range of linkers and also offers custom synthesis and structural modification services.
The conjugation method used in ADCs directly impacts critical properties such as the drug-to-antibody ratio (DAR), conjugation site distribution, and overall stability. BroadPharm offers custom design, synthesis, and detailed analysis of ADCs, including DAR calculation, free drug, and unconjugated antibody quantification.
AOCs combine antibodies, linkers, and oligonucleotides to target extrahepatic tissues, overcoming limitations in liver-targeted drug delivery. We provide custom conjugation services for AOCs, including handling small interfering RNA (siRNA) and antisense oligonucleotides (ASO), along with chemical modification of nucleosides, nucleotides, and phosphoramidites.
PROTACs (Proteolysis Targeting Chimeras) are bifunctional molecules that utilize the ubiquitin-proteasome pathway for targeted protein degradation. PROTAC-antibody conjugates (PAC) enhance selective protein degradation in specific cell types. BroadPharm provides custom synthesis of PROTACs and related products.
PDCs consist of a targeting peptide, linker, and cytotoxic drug. By leveraging the small molecular weight and biodegradability of peptides, PDCs can overcome issues like poor water solubility and slow metabolism. BroadPharm offers customized PDC conjugation services to meet your specific needs.
AECs attach enzymes to antibodies via stable linkers, preserving both the antibody's antigen-binding site and the enzyme’s active site. This technology is used for precise drug delivery to tumors and for detecting specific proteins in complex samples. BroadPharm provides customized AEC conjugation services.
Polymers are widely used in drug delivery due to their biodegradability, biocompatibility, and mechanical strength. Conjugating antibodies or proteins with polymers enhances targeted drug delivery. BroadPharm offers custom polymer conjugation services to optimize delivery capabilities.
By conjugating antibodies or proteins with fluorescent dyes, we enable a range of applications, including bioimaging, immunohistochemistry, and flow cytometry. BroadPharm specializes in the custom design, synthesis, and conjugation of fluorescent dyes to antibodies or proteins.
Biotin binds strongly to avidin and streptavidin, making it ideal for immunochemical techniques. Biotinylated antibodies or proteins are commonly used in immunohistochemistry, signal amplification, and related applications. BroadPharm offers biotinylation services for antibodies and proteins.
With our expertise in organic synthesis and extensive experience in drug conjugation, BroadPharm is dedicated to advancing the research and development of antibody/protein conjugated therapeutics.
Conjugation methods are generally categorized into random conjugation and site-specific conjugation. Random conjugation methods, such as lysine and cysteine-based conjugations, are fast and convenient. However, they can lead to several challenges, including suboptimal therapeutic index, narrower therapeutic windows, and poor stability.
In contrast, site-specific conjugation methods, such as thiol-maleimide chemistry, unnatural amino acids, and various enzyme-catalyzed site-specific conjugation, are designed to address the heterogeneity often seen in ADCs using random conjugation. Random conjugation typically targets surface-exposed lysine residues or interchain disulfide bonds, which can result in a mixture of different conjugates. Site-specific conjugation offers precise control over conjugation sites, producing a more homogeneous mixture that can enhance the potency and overall effectiveness of the ADC.
Table: The characteristics of various conjugation methods applied for ADC*
*Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Sig. Transduct. Target Ther. 2022, 7, 93
HIC-HPLC analysis for antibody mc-VC-pab-MMAE conjugates.
HIC-HPLC analysis for antibody DM1 conjugates.